Corcept Therapeutics
CORT
224 hedge funds and large institutions have $1.81B invested in Corcept Therapeutics in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 64 increasing their positions, 94 reducing their positions, and 34 closing their positions.
40% more call options, than puts
Call options by funds: $2.07M | Put options by funds: $1.48M
0.27% less ownership
Funds ownership: 80.49% → 80.22% (-0.27%)
4% less capital invested
Capital invested by funds: $1.89B → $1.81B (-$80.8M)
3% less funds holding
Funds holding: 232 → 224 (-8)
24% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 34
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
32% less repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 94
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
+$14.2M |
| 2 |
D.E. Shaw & Co
New York
|
+$8.41M |
| 3 |
Two Sigma Advisers
New York
|
+$7.17M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$6.29M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$5.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$36.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$25.9M |
| 3 |
BlackRock
New York
|
-$19.3M |
| 4 |
HSBC Holdings
London,
United Kingdom
|
-$15.2M |
| 5 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$11.9M |
CORT Hedge Fund Activity: Q2 2023 in Review
224 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q2 2023, worth a combined $1.81B — down 4.3% from $1.89B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of CORT and 26 opened new positions — a net loss of 8 holders — while 94 trimmed existing stakes and 64 added.
The largest buyer was Man Group, opening a new position worth an estimated $14.2M. The largest seller was Millennium Management, cutting an estimated $36.1M.
- 224 institutional investors held Corcept Therapeutics (CORT) as of Q2 2023, down from 232 in Q1 2023.
- Funds reported $1.81B of Corcept Therapeutics stock for Q2 2023, down 4.3% quarter-over-quarter.
- 26 funds opened new Corcept Therapeutics positions in Q2 2023 and 34 closed out, a net change of -8 holders.
- The largest Corcept Therapeutics buyer in Q2 2023 was Man Group, an estimated $14.2M added.
- The largest Corcept Therapeutics seller in Q2 2023 was Millennium Management, an estimated $36.1M sold.
Based on aggregated 13F filings for Q2 2023.